Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Revive Therapeutics Ltd C.RVV

Alternate Symbol(s):  RVVTF

Healthcare
Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is... see more

CSE:RVV - Post Discussion

Revive Therapeutics Ltd > 18 trading days left in the quarter.
View:
Post by Trippedstocks on Mar 05, 2021 5:13pm

18 trading days left in the quarter.

and supposedly we are supposed to see:

Q1-21 Submit FDA IND for Phase 2 study for CBD in AIH

Q1-21 Psilocybin oral thin film scale-up

Q1-21 Psilocybin research results in TBI (Concussion)

Q1-21 Begin Phase 1 study - Psilocybin in Meth Disorder

As well as the meeting agenda/info/proxy materials

could be an exciting and interesting 3 weeks... Or a disappointing 3 weeks. We shall see.
Comment by cool888 on Mar 05, 2021 5:40pm
I would say Exciting, Interesting AND Rewarding weeks ahead !! GLTA !!!
Revive Therapeutics Ltd